Marta Batus is an Oncology physician affiliated with Rush University Medical Center. OpenAlex indexes 160 publications with 890 citations (h-index 17).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
35.4%Kinase inhibitor31%Tagrisso75%Pazopanib Hcl14%Alecensa11%Part D<11 patientsAlkylating Drug4.5%Yondelis100%Part D<11 patientsMetabolism & gastrointestinal
20.8%Serotonin-3 Receptor Antagonist14%Ondansetron Hcl100%Part D≥30 patientsCorticosteroid3.6%Prednisone100%Part D<11 patients+ 1 more class in this area
Nervous system
16.1%Phenothiazine11.9%Prochlorperazine Maleate100%Part D≥31 patientsOpioid Agonist4.2%Tramadol Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Frequency of weight and body composition increases in advanced non‐small cell lung cancer patients during first line therapy
Journal of Cachexia Sarcopenia and Muscle
2024 - OA01.04 Five-Year Survival in Patients with ES-SCLC Treated with Atezolizumab in IMpower133: Imbrella a Extension Study Results
Journal of Thoracic Oncology
2023 - What is the clinical impact of staging and surveillance PET‐CT scan findings in patients with bone and soft tissue sarcoma?
Journal of Surgical Oncology
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Theodore Pincus, MD
Rush University Medical Center
Neelum Aggarwal, MD
Rush University Medical Center
Philip Bonomi, MD
Rush University Medical Center
Steven Flamm, MD
Rush University Medical Center
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”